Zotarolimus (ABT-578) eluting stents.
Drug-eluting stents have revolutionized the field of interventional cardiology and have provided a significant innovation for preventing coronary artery restenosis. Polymer coatings that deliver anti-proliferative drugs to the vessel wall are key components of these revolutionary medical devices. This article focuses on the development of stents which elute the potent anti-proliferative agent, zotarolimus, from a synthetic phosphorylcholine-based polymer known for its biocompatible profile. Zotarolimus is the first drug developed specifically for local delivery from stents for the prevention of restenosis and has been tested extensively to support this indication. Clinical experience with the PC polymer is also extensive, since more than 120,000 patients have been implanted to date with stents containing this non-thrombogenic coating. This review provides background on pre-clinical studies with zotarolimus, on the development of the biocompatible PC polymer and on the clinical trials conducted using two stent platforms which deliver this drug to patients with coronary artery disease.
Cardiovascular Systems Research, Abbott Laboratories, 200 Abbott Park Road, Department AVD-5, AP-52-2N, Abbott Park, Illinois 60064-6215, USA. sandra.e.burke@abbott.com
Sandra E
SE
Burke
Richard E
RE
Kuntz
Lewis B
LB
Schwartz
D023903:Coronary Restenosis / Q000188:drug therapy / Q000517:prevention & control*; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015607:Stents
C489443:zotarolimus; D020123:Sirolimus